Fennec Pharmaceuticals Inc. will release its second quarter 2026 financial results on August 11, 2026, before U.S. markets open. The company, which specializes in treatments to reduce chemotherapy-induced hearing loss, will host a conference call and webcast to discuss its financial and business performance. Investors can access the live webcast via the company’s website, with a replay available for 30 days. This update follows Fennec's ongoing commercialization of PEDMARK®, a drug approved in the U.S. and Europe to protect cancer patients from ototoxicity caused by platinum-based chemotherapy.
Randstad reported revenue and earnings that exceeded expectations, driven by improving business trends and key labor markets. This positive performance signals momentum in the employment services sector. RBC Capital maintained a 'Sector Perform' rati...
MSC Industrial Supply reported strong Q4 results with revenue rising 10.3% year-over-year to about $1.08 billion, surpassing estimates. Adjusted earnings per share increased to $1.45 from $1.09, also beating expectations. Full-year sales grew 6.4% to...
ARMOUR Residential REIT reported a $327 million net loss for Q3 2026, driven by higher interest rates that reduced its book value by 17% to $14.55 per share. Despite the loss, the company earned $83.7 million in net interest income and $102.3 million...
Southern Company, an electric and gas utility, clarified it has no connection to a Mexican silver mining project, dispelling recent rumors. HSBC initiated coverage of Southern Company with a Buy rating, with shares trading at $90.39 at the time. The ...
Remittix is set to add 41 new fiat currencies to its PayFi ecosystem, enhancing crypto-to-bank and bank-to-crypto transactions globally ahead of its November 24 RTX launch. This expansion aims to support more international markets and users, includin...
